Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.35 |
| ▸ | RXRA | P19793 | 5/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21260712 | 0.87 | GABRA1 (0.42) | GABRA1GABRB2PTPN7DUSP3HTR2A | |
| SCHEMBL5018902 | 0.87 | AR (0.44) | GABRA1GABRB2PTPN7DUSP3TRPM8 | |
| SCHEMBL18266749 | 0.78 | LOXL2 (0.40) | KCNH2PTPN7DUSP3GRIN1GRIN2B | |
| SCHEMBL2623873 | 0.77 | GABRA1 (0.48) | GABRA1GABRB2ARHTR2AHTR2B | |
| SCHEMBL9176216 | 0.77 | GABRA1 (0.48) | GABRA1GABRB2ARHTR2AHTR2B | |
| SCHEMBL18701030 | 0.76 | GABRA1 (0.42) | GABRA1GABRB2HTR2A | |
| SCHEMBL6600224 | 0.76 | KIF11 (0.49) | GABRA1GABRB2HTR2AHTR2CHTR2B | |
| SCHEMBL12615668 | 0.76 | PTGS1 (0.39) | GABRA1GABRB2ARHTR2A | |
| SCHEMBL13863080 | 0.75 | GABRA1 (0.41) | GABRA1GABRB2PTPN7DUSP3RXRA | |
| SCHEMBL8252056 | 0.73 | GABRA1 (0.46) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | GABRA1 2275/4885GABRB2 1306/4885KCNH2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.